Relay Therapeutics' Zovegalisib Triplet Shows 44% ORR, Advances to Phase 3 in Metastatic Breast Cancer
RLAY has more than doubled off its 52-week low of $2.67.
Summary
Relay Therapeutics announced compelling clinical data for its zovegalisib plus atirmociclib triplet combination, leading to plans for Phase 3 development in frontline PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The data showed a 44% objective response rate (ORR) in heavily pre-treated, median third-line patients, with a favorable safety and tolerability profile. This advancement to Phase 3 is a significant de-risking event and a major value driver for a clinical-stage biotech company, building on the prior Breakthrough Therapy Designation for zovegalisib. The promising efficacy and tolerability, particularly the ORR approaching current standard of care in frontline settings, suggests a strong competitive profile. The company has also secured a supply agreement with Pfizer for atirmociclib. Investors will now watch for the initiation of the Phase 3 trial, expected in early 2027, pending regulatory feedback.
At the time of this announcement, RLAY was trading at $15.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $2.67 to $17.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.